Burkitt's Lymphoma

Highly aggressive MYC-driven B-cell NHL — t(8;14) translocation, three clinical variants, and curative intensive immunochemotherapy

Key Points

• Burkitt's lymphoma is one of the fastest-growing human tumors (doubling time ~24 hours), driven in virtually all cases by MYC translocation — most commonly t(8;14)(q24;q32), juxtaposing MYC with the IGH locus.
• Three clinical variants exist: endemic (African; EBV-associated; jaw/facial bone tropism), sporadic (worldwide; ileocecal/abdominal mass), and immunodeficiency-associated (HIV; often disseminated with CNS involvement).
• Despite its aggressive biology, Burkitt's lymphoma is highly curable with intensive, dose-dense immunochemotherapy — long-term OS exceeds 70–90% in low-risk patients treated at experienced centers.
• Regimens such as DA-EPOCH-R, CODOX-M/IVAC-R, Hyper-CVAD-R, and the BFM/LMB protocols (in children) are used; all include CNS prophylaxis given the high rate of CNS dissemination.
• Tumor lysis syndrome (TLS) is the most life-threatening early complication and requires aggressive prophylaxis — aggressive hydration, allopurinol or rasburicase, and careful electrolyte monitoring before and during the first cycle.
• CNS involvement is present in 10–20% of patients at diagnosis and is an adverse prognostic factor; all patients receive CNS prophylaxis (intrathecal chemotherapy ± high-dose methotrexate).

Molecular Biology and Pathogenesis

Burkitt's lymphoma is the paradigmatic MYC-driven lymphoma. MYC encodes a transcription factor that broadly activates RNA Pol I, II, and III, driving cell cycle progression, ribosome biogenesis, and metabolic reprogramming. Constitutive MYC overexpression downstream of immunoglobulin locus enhancers renders cells dependent on continuous proliferation — explaining the extremely short doubling time. The canonical translocation t(8;14)(q24;q32) is present in ~80% of cases, placing MYC under control of the IGH heavy chain enhancer. Variant translocations involving the IGK (t(2;8)) or IGL…

Clinical Variants and Presentation

**Endemic (African) BL:** Occurs in equatorial Africa and Papua New Guinea, accounting for the majority of childhood lymphoma in these regions. Strongly associated with EBV (>95% of cases). Classically presents with jaw and facial bone masses, orbital tumors, and abdominal involvement. Predominantly affects children aged 4–7 years. Malaria-driven immune dysregulation facilitates EBV-driven B-cell expansion and predisposes to MYC translocation. **Sporadic BL:** The most common form in developed countries. Peaks in children and young adults; a second peak in older adults exists. EBV is…

Diagnosis and Staging

Diagnosis is established by tissue biopsy with histopathology, immunohistochemistry, and molecular studies. Morphology shows the characteristic medium-sized B cells with starry sky pattern. Immunophenotype: CD20+, CD10+, BCL6+, BCL2−, TdT−, Ki-67 near 100%. The absence of BCL2 expression distinguishes BL from DLBCL with concurrent BCL2 and MYC rearrangements (double-hit lymphoma), which carries a worse prognosis and is treated differently. Molecular confirmation of MYC translocation by FISH is required. FISH panels should include BCL2 and BCL6 to exclude double/triple-hit lymphoma. If FISH…

Treatment

**Tumor Lysis Syndrome Prophylaxis (Critical First Step)** All patients with BL are at high risk for TLS. Before initiating chemotherapy: aggressive IV hydration (200–300 mL/hr), rasburicase (urate oxidase) for high-risk patients, and allopurinol for low/intermediate-risk patients. Electrolytes (potassium, phosphorus, uric acid, creatinine) must be monitored every 4–8 hours during the first 24–72 hours of treatment. Cardiac monitoring is required. **Intensive Immunochemotherapy** All regimens incorporate rituximab (anti-CD20) with intensive dose-dense chemotherapy. Major regimens include: -…

Prognosis and Survivorship

Burkitt's lymphoma, despite its aggressive biology, is one of the most curable lymphomas when treated with appropriate intensive therapy at experienced centers. In children and adolescents, cure rates exceed 90% with BFM or LMB protocols. In adults, 3-year OS with DA-EPOCH-R or CODOX-M/IVAC-R approaches 70–85% in low-to-intermediate risk patients, though outcomes decline with CNS involvement, poor performance status, and high IPI score. Adverse prognostic factors include: CNS disease at diagnosis, advanced stage (IV), high LDH, poor performance status, and age >60 years. Patients with CNS…